





DGRI / SSRI A4 1 09/10/2025



## The Strategy at a Glance





**Ensuring France's Health** 

Allow access to innovative therapies in France

Ensuring the sustainability of the french health care system

Making France a European leader in drug





« Enable patients to benefit from the best treatments »


« Position France as a European leader in biotherapies and their bioproduction»



## The Strategy at a Glance



A strategy designed with academics, industry and health sector.







#### **2025-2030 Objectives**

Double the number of jobs in the sector ( 20,000)

2018: 10,000 jobs

Produce at least 60 biomedicines in France

Currently 47 biomedicines products in France

Emergence of an unicorn, 5 Mid-size Cies and 5 new biotechs

Ensure a constant flow of innovation from academic research

Ensure and accelerate developments and industrialise production in France

Actively support the sector by creating and financing dedicated organizations

Training support for new talents from technicians to PhD

Reglementary support to facilitate clinical trials and market access



#### **Priorities**




#### Four themes priority:

- · Biotechnologies in oncology;
- Innovations in gene and cell therapy (excluding oncology);
- Systems for optimizing existing technologies, including new expression systems for producing these biomedicines;
- The development of more efficient production units and tools for optimizing culture systems and bioproduction processes.











### **Strategy Tools**

#### TRL SCALE

Dedicated Research programs Tech transfert program support

Public Private partnership innovative programs

Industrialisation and capacity building call

Tech transfert : 8 core facilities dedicated to tech transfert in Biot. & ATMP

GENOTHER Biocluster : consolidate a ecosyteme of :

Core facilities / start-up dev. activities / training dedicated to ATMP / investors

Extra Strategy: IPPCEI Med4Cure (RNAVaccine and ATMP)


Training support for new talents from technicians to PhD




# key figures



09/10/2025






75% Committed funds

**130 Funded Projects** in R&D, Innovation and Industrialization

**6** Training Projects

> 400 Partners

3rd anniversary







## Need to act at the european level

France is strongly active and need to act with other countries at the european level.

France will participate to the construction of the European Biotech act.

France encourage International action through international research programs and international training programs.







#### THANK YOU FOR YOUR ATTENTION

Ministry of Higher Education and Research:



Biotherapy and Bioproduction Strategy:



Health Innovation Agency:

